Literature DB >> 82353

Hunan wart-virus antibodies in patients with genital and skin warts.

S Pyrhönen.   

Abstract

A comparative follow-up study of the antibody response against human wart-virus was performed, using the immunodiffusion and complement fixation methods on patients with condylomas and skin warts. By the immunodiffusion method, 13% of the patients with skin warts and 3% of the patients with condylomas showed greater than or equal to fourfold increase of antibody titre during the follow-up of 2--35 months. The findings show some typical features of the weak antibody response of a chronic virus infection and suggest a serological overlapping between condyloma viruses and certain group of skin wart-viruses. The antibody prevalence in age-matched controls is shown to be significantly higher than that in the wart or condyloma patients' initial serum samples. This is indicative of the protective function of antibodies against warts and condylomas. Also the analysis of the history of warts in patients with condylomas suggests that protection against condylomas can be acquired from previous warts, evidently by immunological mechanisms. In a control group of medical students, human wart-virus antibodies were frequently (52%) found in subjects without any history of warts. This finding supports the view that human wart-virus can frequently induce latent or subclinical infections in human beings.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 82353

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  7 in total

1.  Human antibodies react with an epitope of the human papillomavirus type 6b L1 open reading frame which is distinct from the type-common epitope.

Authors:  S A Jenison; X P Yu; J M Valentine; D A Galloway
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

2.  Levels of immunoglobulin G antibodies against defined epitopes of the L1 and L2 capsid proteins of human papillomavirus type 6 are elevated in men with a history of condylomata acuminata.

Authors:  A Wikström; C Eklund; G Von Krogh; P Lidbrink; J Dillner
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

3.  Development of type-specific and cross-reactive serological probes for the minor capsid protein of human papillomavirus type 33.

Authors:  C Volpers; M Sapp; C A Komly; P Richalet-Secordel; R E Streeck
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

4.  Identification of immunoreactive antigens of human papillomavirus type 6b by using Escherichia coli-expressed fusion proteins.

Authors:  S A Jenison; J M Firzlaff; A Langenberg; D A Galloway
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

5.  Detection of respiratory syncytial virus in nasopharyngeal secretions by inhibition of enzyme-linked immunosorbent assay.

Authors:  A Hornsleth; E Brenøe; B Friis; F U Knudsen; P Uldall
Journal:  J Clin Microbiol       Date:  1981-11       Impact factor: 5.948

6.  Autogenous vaccine therapy for condyloma acuminatum. A double-blind controlled study.

Authors:  M D Malison; R Morris; L W Jones
Journal:  Br J Vener Dis       Date:  1982-02

7.  Production of antiserum to respiratory syncytial virus polypeptides: application in enzyme-linked immunosorbent assay.

Authors:  A Hornsleth; P C Grauballe; B Friis; J Genner; I R Pedersen
Journal:  J Clin Microbiol       Date:  1981-11       Impact factor: 5.948

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.